|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
WO2000009132A1
(en)
*
|
1998-08-12 |
2000-02-24 |
Smithkline Beecham Corporation |
Calcilytic compounds
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
CA2416976C
(en)
|
2000-08-11 |
2008-05-20 |
Wyeth |
Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
|
|
BR0114323A
(pt)
|
2000-09-29 |
2003-07-01 |
Glaxo Group Ltd |
Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
AU2006224295A1
(en)
*
|
2005-03-17 |
2006-09-21 |
Pfizer, Inc. |
N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
US8067415B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
WO2007053498A1
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
EP2318369A1
(en)
|
2008-06-24 |
2011-05-11 |
TopoTarget A/S |
Squaric acid derivatives as inhibitors of the nicotinamide
|
|
WO2010023307A1
(en)
|
2008-08-29 |
2010-03-04 |
Topotarget A/S |
Novel urea and thiourea derivatives
|
|
CA2768338A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
PH12013500412A1
(en)
|
2010-09-03 |
2013-04-22 |
Forma Tm Llc |
Novel compounds and compositions for the inhibition of nampt
|
|
TW201216963A
(en)
|
2010-09-03 |
2012-05-01 |
Forma Therapeutics Inc |
Novel compounds and compositions for the inhibition of NAMPT
|
|
RU2016116533A
(ru)
|
2010-09-03 |
2018-11-30 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
JP5791725B2
(ja)
*
|
2010-09-29 |
2015-10-07 |
インターベット インターナショナル ベー． フェー． |
Ｎ−ヘテロアリール化合物
|
|
MX2013005479A
(es)
|
2010-11-15 |
2013-06-12 |
Abbvie Inc |
Inhibidores de nampt.
|
|
JP6117104B2
(ja)
|
2010-11-15 |
2017-04-19 |
アッヴィ・インコーポレイテッド |
Ｎａｍｐｔおよびｒｏｃｋ阻害薬
|
|
RU2616612C2
(ru)
|
2011-05-04 |
2017-04-18 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
RU2617643C2
(ru)
|
2011-05-09 |
2017-04-25 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
WO2013170115A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Pyridazine and pyridine derivatives as nampt inhibitors
|
|
US9334264B2
(en)
|
2012-05-11 |
2016-05-10 |
Abbvie Inc. |
NAMPT inhibitors
|
|
MX2014013734A
(es)
|
2012-05-11 |
2015-06-10 |
Abbvie Inc |
Inhibidores de nampt.
|
|
JP2015516436A
(ja)
|
2012-05-11 |
2015-06-11 |
アッヴィ・インコーポレイテッド |
Ｎａｍｐｔ阻害薬
|
|
US9938258B2
(en)
|
2012-11-29 |
2018-04-10 |
Karyopharm Therapeutics Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
ES2935035T3
(es)
|
2013-07-03 |
2023-03-01 |
Karyopharm Therapeutics Inc |
Compuestos de benzofuranilo y benzoxazolilo sustituídos y usos farmacéuticos de los mismos
|
|
US9994558B2
(en)
|
2013-09-20 |
2018-06-12 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
US10363247B2
(en)
|
2015-08-18 |
2019-07-30 |
Karyopharm Therapeutics Inc. |
(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
BR112019006778A2
(pt)
|
2016-10-18 |
2019-10-15 |
Seattle Genetics Inc |
Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
MA51189A
(fr)
|
2017-04-27 |
2020-03-04 |
Seattle Genetics Inc |
Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
|
|
CA3089754A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
CN119930509A
(zh)
|
2019-11-06 |
2025-05-06 |
治疗方案股份有限公司 |
靶向癌症干细胞的癌症治疗
|
|
AU2022273050A1
(en)
|
2021-05-13 |
2023-11-09 |
Remedy Plan, Inc. |
Nampt inhbitors and uses thereof
|